Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation

The frequency of poor outcomes in relapsed leukemia patients underscores the need for novel therapeutic approaches. The FDA-approved immunosuppressant FTY720 limits leukemia progression by activating protein phosphatase 2A and restricting nutrient access. Unfortunately, FTY720 cannot be re-purposed...

Descripción completa

Detalles Bibliográficos
Autores principales: McCracken, Alison N., McMonigle, Ryan J., Tessier, Jérémie, Fransson, Rebecca, Perryman, Michael S., Chen, Bin, Keebaugh, Andrew, Selwan, Elizabeth, Barr, Sarah A., Kim, Seong M., Roy, Saurabh G., Liu, Gang, Fallegger, Daniel, Sernissi, Lorenzo, Brandt, Cordelia, Moitessier, Nicolas, Snider, Ashley J., Clare, Simon, Müschen, Markus, Huwiler, Andrea, Kleinman, Michael T., Hanessian, Stephen, Edinger, Aimee L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332311/
https://www.ncbi.nlm.nih.gov/pubmed/27573555
http://dx.doi.org/10.1038/leu.2016.244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332311/
https://www.ncbi.nlm.nih.gov/pubmed/27573555
http://dx.doi.org/10.1038/leu.2016.244

Ejemplares similares